Back to top

messenger-rna: Archive

Zacks Equity Research

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab

Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.

GSKNegative Net Change PFENegative Net Change MRNAPositive Net Change ALLOPositive Net Change